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Abstract
The pathogenesis of classical Hodgkin lymphoma (cHL) involves environmental and genetic factors. To explore the role of
the human leukocyte antigen (HLA) genes, we performed a case-control genotyping study in 338 Dutch cHL patients using
a PCR-based sequence-specific oligonucleotide probe (SSOP) hybridization approach. The allele frequencies were compared
to HLA typings of more than 6,000 controls. The age of the cHL patients varied between 13 and 81 years with a median of
35 years. Nodular sclerosis subtype was the most common subtype (87%) and EBV was detected in 25% of the cHL patients.
HLA-B5 was significantly increased and HLA-DR7 significantly decreased in the total cHL patient population as compared to
controls. Two class II associations were observed to be specific for the EBV2 cHL population with an increase of HLA-DR2
and HLA-DR5. Allele frequencies of HLA-A1, HLA-B37 and HLA-DR10 were significantly increased in the EBV+ cHL
population; these alleles are in strong linkage disequilibrium and form a common haplotype in Caucasians. The allele
frequency of HLA-A2 was significantly decreased in the EBV+ cHL population. Analysis of haplotypes with a frequency of
.1% revealed a significant increase of HLA-A2-B7-DR2 in EBV2 cHL as compared to controls. SSOP association analysis
revealed significant differences between EBV+ and EBV2 cHL patients for 19 probes that discriminate between HLA-A*01
and HLA-A*02. In conclusion, the HLA-A1 and HLA-A2 antigens and not specific single nucleotide variants shared by
multiple alleles are responsible for the association with EBV+ cHL. Furthermore several new protective and predisposing
HLA class I and II associations for the EBV+, the EBV2 and the entire cHL population were identified.
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Introduction
Classical Hodgkin lymphoma (cHL) is a typical multi-factorial
disease with both environmental and genetic factors acting
together to cause disease [1,2]. Epidemiological studies reporting
familial clustering of cHL [3] and racial variation in the incidence
of cHL [4] give substantial support for an inherited risk to cHL.
Genetic associations with specific Human Leukocyte Antigen
(HLA) alleles have been reported in both sporadic and familial
cHL [5–7].
Epstein Barr virus (EBV) is a well-established causal factor in a
subset of cHL patients [8]. The expression pattern of EBV genes in
Hodgkin Reed-Sternberg (HRS) cells is restricted to the two latent
membrane proteins (LMP1 and LMP2) and the EBV nuclear
antigen 1 (EBNA1) [8]. Despite the lack of immunodominant EBV
proteins, LMP and EBNA1-specific T cell responses can be
efficiently induced in the context of specific HLA class I or class II
molecules [9–11]. The extreme diversity of HLA genes influences
both the affinity and specificity of antigenic peptide binding and is
responsible for variations in host anti-viral immune defenses.
Genetic variation in host anti-viral immune responses related to
HLA polymorphisms might be an important contributor to the
development of virally induced malignancies.
Initial HLA association studies in cHL were performed without
taking EBV status into account and associations of HLA-A1,
HLA-B5, HLA-B8 and HLA-B18 with cHL have been described,
although the degree of reproducibility was low [6,12–14]. More
recently, we focused on EBV stratified cHL subgroups in a genetic
screening study of the entire HLA region [5]. In a subsequent
finescreening analysis we found a strong association of specific
HLA-A alleles with susceptibility to EBV+ cHL in Dutch and
English patients [15]. HLA-A1 was associated with an increased
risk for EBV+ cHL, whereas HLA-A2 was associated with a
decreased risk for EBV+ cHL [16]. This association was confirmed
in 934 Scandinavian and English cHL patients in a study by
Hjalgrim et al [17]. In two recently performed genome wide
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association studies (GWAS) in cHL patients, the most significantly
associated SNP (rs6903608) was located within the HLA class II
region [18,19].
In the present study, we performed an extensive screening of the
HLA class I and II genes to investigate possible associations of
HLA alleles in the total, the EBV+, and the EBV2 cHL
(sub)populations. Furthermore, we intended to establish whether
specific single nucleotide polymorphism (SNP) positions in the
HLA genes that might be shared by multiple HLA alleles are




All patients gave written informed consent in accordance with
the Declaration of Helsinki and the protocols were approved by
the medical ethics board of the University Medical Center,
Groningen.
Patients and controls
183 cHL patients from the northern region of the Netherlands
who participated in the previous population-based genotyping
study [5] were included in the present study. 155 additional
patients diagnosed and/or treated between 2000 and 2010 at the
University Medical Center Groningen in the northern region of
the Netherlands were also included. Data on gender, age, and
histopathological diagnosis was available for all these patients. No
data were available on family history. Classification according to
the WHO was performed consistently with the previous study and
cHL cases that could not be unequivocally subtyped (usually
because of little tissue) were classified as cHL not otherwise
specified (NOS) (Table 1). The presence of EBV in tumor cells was
detected in formalin fixed paraffin embedded tissue sections by in-
situ hybridization (ISH) with a fluorescin-conjugated PNA probe
specific for the EBV-encoded EBER RNAs (DAKO, Glostrup,
Denmark). The control group consisted of blood bank donors from
the same geographical region typed for HLA-A (n= 7,554), HLA-
B (n= 7,554) and HLA-DR (n= 6,559) by serological methods and
in case of unclear results or apparent class II homozygosity
additionally by DNA based methods.
HLA genotyping
Blood samples of cHL patients were collected and genomic
DNA was extracted from the peripheral blood mononuclear cell
pellets using standard laboratory protocols. The HLA genotype
was analyzed at medium resolution by a polymerase chain
reaction-based sequence-specific oligonucleotide probe hybridiza-
tion (PCR-SSOP) approach using commercial kits (Gen-Probe,
San Diego, CA) and Luminex xMAP technology (Luminex Corp.,
Austin, TX). The assays were performed according to the
manufacturer’s instruction in a European Federation for Immu-
nogenetics accredited laboratory. Briefly, biotin-labeled amplifica-
tion products were generated for exon 2 (for HLA-DRB, HLA-
DPB1) and exon 3 (for HLA-A, HLA-B, HLA-Cw and HLA-
DQB1) of the HLA genes, followed by a hybridization reaction
with a series of SSOPs. Of the 401 PCR-SSOP probes 43 were
either positive or negative for all samples and were therefore
excluded from the analyses. Of the 358 included probes, 63 were
for the HLA-A locus, 83 for the HLA-B locus, 53 for the HLA-C
locus, 72 for the HLA-DRB locus, 41 for the HLA-DQB1 locus
and 46 for the HLA-DPB1 locus. Each probe covered 1 to 3 SNP
positions. The HLA alleles were defined by specific hybridization
patterns of multiple probes. All analyses were restricted to the
broad alleles because of missing split allele data for a substantial
proportion of the control population. HLA genotype was
ascertained according to the manufacturers instructions using the
manufacturer’s software and additionally by the SCORE software
[20], enabling the exclusion of probes with borderline hybridiza-
tion signals. The presumed antigen or T cell receptor binding
function of the SNPs were identified according to Bjorkman and
Parham [21].
HLA allele frequencies of the cHL patients were deducted from
the PCR-SSOP genotyping data based on the Nomenclature for
factors of the HLA system (http://hla.alleles.org/nomenclature/
naming.html). In case of ambiguous results, the allele combination
only consisting of common and well documented alleles [22] were
used. For HLA-DPB1 one ambiguity remained (DPB1*04:02/
105:01) which was analyzed as one group of alleles.
Statistical analysis
For each individual PCR-SSOP association with EBV status
was tested by logistic regression in PLINK v1.07 [23] (http://
pngu.mgh.harvard.edu/purcell/plink/) with EBV status as a
dependent variable, SSOP as an independent variable, and age
and histopathological diagnosis of cHL as confounding covariates.
Linkage disequilibrium (LD) between the SSOPs was determined
using the measures D’ and r2. The first measure reflects the
evolutionary history of the SSOP pairs in which a D’ of 1 implies
no recombination between the two SSOPs. The latter measure is
the correlation between SSOPs and reflects if SSOP associations
are independent of each other (higher r2 means less indepen-
dence).
Allele frequencies of HLA-A, HLA-B and HLA-DR of the total
cHL group, the EBV+ subgroup and the EBV2 subgroup were
compared with allele frequencies of the controls and significant
differences were assessed by Chi-square tests and odds ratio (OR)
to quantify the difference and estimate risk were determined.
Allele frequencies for HLA-C, HLA-DP and HLA-DQ of the
controls were not available. All HLA genes were included for the
analysis between EBV+ and EBV2 cHL patients. Alleles with a
frequency ,1% in our population were excluded for all these
analyses.
Haplotype frequencies for HLA-A-B-DR were estimated in the
controls, the cHL patients, the EBV+ and the EBV2 patients
using PHASE v2.124,25. For the comparison between EBV+ and
the EBV2 patients we analyzed haplotype frequencies for HLA-
A-B-C-DR-DQ-DP and for HLA-A-B-C-DR-DQ without DP
because of the known recombination hotspot between DQ and
Table 1. Distribution of sex, histological subtype and age in
cHL population stratified by EBV status.









Median age (range) 35 (13–81)
doi:10.1371/journal.pone.0039986.t001
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DP. Next the estimated counts (calculated by sample size x
estimated frequencies) of each haplotype were compared between
cHL, EBV+ and EBV2 patients and controls and between EBV+
and EBV2 patients using a chi-square test and the OR and 99.9%
CI were determined. Only those haplotypes with a frequency of
.1% (in patients plus controls) were considered to be relevant in
the analysis.
Our patient cohort was used in the replication series of the
recently published GWAS that identified the HLA class II SNP
rs6903608 as a highly significant susceptibility marker for cHL
[18,18]. We now compared the SNP alleles (C and T) with the
HLA typing data to investigate their linkage disequilibrium (LD).
Combined HLA typing and SNP data were available for 278 cHL
patients. Two-marker haplotypes of the SNP rs6903608 and the
HLA typing were constructed per gene using PHASE v2.1
[24,25]. Frequencies of HLA typing among haplotypes with a C
allele and a T allele at rs6903608 were compared per HLA typing
using the Chi-square test.
For each phenotype and PCR-SSOP a test was performed,
hence a correction for multiple testing was required. Because LD
exists between the PCR-SSOPs and between the HLA pheno-
types, and because the HLA-phenotypes are derived from the
PCR-SSOPs, a Bonferroni test for 401 PCR-SSOPs and 74 HLA
phenotypes would be too conservative. Therefore, we considered
p-values smaller than 0.001 to be significant at a level of 5% and p-
values ,0.003 to be suggestive for association. Further more
99.9% confidence intervals for the Ors were determined.
Results
Clinicopathological characteristics
Characteristics of the patient population in terms of age, gender
and histopathological subtype in relation to EBV status is
summarized in Table . EBV was present in the tumor cells in 78
(25%) of the 311 cHL patients (for 27 patients EBV status was
unknown). In the total group, median age at diagnosis was
35 years (range 13 to 81) and the percentage of males was 52%.
Age at time of diagnosis was similar in the EBV+ and EBV2
group, i.e. 37 (range 17 to 70) in EBV+ and 32 (range 13 to 81) in
EBV2. 43 of 338 cHL patients could not be subtyped and were
designated cHL NOS. In the remaining patients, nodular sclerosis
(NS) was the most common subtype accounting for 87%. Mixed
cellularity (MC) and lymphocyte rich (LR) subtypes were less
common with frequencies of 10% and 3%, respectively. The
lymphocyte depletion (LD) subtype was absent in this patient
group. These characteristics are largely consistent with those
published for Caucasian cHL populations.
Allele frequency differences compared to controls
An overview of all allele frequency data, OR and p-values is
given in Supplementary Table S1. HLA allele frequencies in the
control population were consistent with previously published data
[26]. HLA phenotype frequencies including OR and p-values are
given in Supplementary Tables S2, S3, S4 and Supplementary
Figure S1. This paper focuses on the HLA allele frequency
analysis. Overall, the significant associations observed in the allele
frequency analysis were similar to the phenotype frequency
analysis, with some minor differences only in the overall cHL
population.
In the cHL patient group the allele frequencies of HLA-B5 and
HLA-DR2 were significantly increased as compared to the
controls (8.3% vs 5.3%; p= 8.9x1024, 21.7% vs 16.4;
p = 3.161024). The HLA-DR7 allele frequency was significantly
decreased (5.2% vs 10.1%; p= 3.761025) (Table 2; Figure 1). In
EBV2 cHL patients a significantly increased frequency was
observed for HLA-DR2 and HLA-DR5 compared to controls
(22.9% vs 16.4%; p= 2.161024, 14.3% vs 9.3%; p= 3.661024)
(Table 3, Figure 1). For the EBV+ cHL subgroup strong
associations were observed for HLA-A1, HLA-A2, HLA-B37
and HLA-DR10 (Table 3; Figure 1). In contrast to the significant
increased frequency of HLA-DR5 in the EBV2 cHL subgroup,
the frequency was reduced in the EBV+ cHL subgroup, although
not significant. The HLA-A1 frequency was increased compared
to the controls (33.3% vs 17.7%; p= 3.561027), whereas the
HLA-A2 frequency was decreased (16.0% vs 32.0%;
p= 2.161025) in EBV+ cHL. For HLA-B37 (8.3% vs 1.8%;
p= 3.361029) and HLA-DR10 (3.8% vs 0.9%; p= 1.461024) an
increased frequency was observed in the EBV+ cHL patients as
compared to the controls.
Differences in HLA allele frequencies between EBV+ and
EBV2 cHL patients
Comparison of the HLA allele frequencies revealed four
significant differences between the EBV+ and EBV2 cHL
subgroups (Supplementary Table S1). The HLA-A1 frequency
was significantly increased (33.3% vs 18.3%; p= 9.261025) and
the HLA-A2 frequency was significantly decreased (16.0% vs
33.0%; p= 5.261025). In addition, we observed a significantly
increased frequency for HLA-B37 (8.3% vs 2.2%; p= 4.861024)
(Table 4).
Figure 1. Odds ratios and 99.9% confidence intervals of the
genotype allele frequencies. The graph shows the (nearly)
significant differences between the controls and either the total cHL
patient group (grey), the EBV+ (black), or the EBV2 (white) subgroup of
patients. The size of the diamonds reflects the allele frequency.
doi:10.1371/journal.pone.0039986.g001
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Haplotype analysis
Haplotype frequency data are shown in Supplementary
Table S5. For the comparison of the total cHL population versus
controls no significant associations were observed for haplotypes
with a frequency of .1%. Two suggestive differences were
observed, i.e. A2-B7-DR2 (3.2% vs 5.3%, p= 2.161023) and A2-
B40-DR6 (2.1% vs 0.4%, p= 1.961023). The A2-B7-DR2
haplotype was significantly increased in controls vs EBV2 cHL,
i.e. 3.2% vs 6.7% (p= 2.2610–5), whereas none of the haplotypes
showed a significant difference between EBV+ cHL and controls.
Overall, the p-values for the individual HLA alleles revealed much
stronger associations as compared to the associations observed for
the haplotype analysis.
Association analysis of individual PCR-SSOPs in EBV+ and
EBV2 cHL patients
Analysis of each of the 358 PCR-SSOPs revealed a significant
difference between EBV2 and EBV+ cHL patients for 19 HLA-A
gene PCR-SSOPs (Figure 2; Supplemental Table S1). Ten of the
PCR-SSOPs were specific for the HLA-A*01 allele and were more
common in EBV+ cHL patients, while the other nine PCR-SSOPs
specific for the HLA-A*02 allele were less common in this patient
group (Table 2). Interestingly the most significant SSOP (C295) is
not strongly correlated with any of the other SSOPs (r2,0.4
except for pair C295-C331 [r2 = 0.70]) (Figure 3). This implies that
the association of C331 is likely caused by LD with C295. These
probes share a specificity for HLA-A*23/*A24 next to HLA-A*01.
In addition, we observed a second independent association for the
SSOPs C395 and C211, which were the only two probes that
shared specificity for HLA-A*03. A third independent association
was shown for the SSOPs C378, C325, C375, C281 and C215.
Specificity of these SSOPs is largely restricted to HLA-A*01. The
C332 SSOP showed an intermediate association. The HLA-A*02
specific SSOPs are strongly correlated with each other (most pairs
have r2.0.8, for all pairs r2.0.3) and hence there is likely only one
signal that is causing these associations. No LD is observed
between the HLA-A*01 and the HLA-A*02 specific SNPs
(r2,0.23; D’,0.53).
The 19 SSOPs with significant differences contained polymor-
phic residues within nine of the HLA-A*02-specific and ten of the
HLA-A*01 specific SSOPs that are located at key positions in the
peptide binding pockets of the HLA molecules (Table 5). PCR-
SSOPs that were less specific for the HLA-A*01 or HLA-A*02
alleles showed a similar trend in the OR as the significant PCR-
SSOPs but with lower p-values (Supplementary Table S1).
Analysis of the NS and the non-NS subgroups separately for the
most significant PCR-SSOPs revealed trends similar to the total
group albeit with lower p-values because of the smaller group sizes.
Remarkably, the ORs in the non-NS group were more
pronounced (0.21–0.23 for the HLA-A*02 SSOPs and 4.74–8.06
for HLA-A*01 SSOPs) than the ORs in the NS subgroup (0.36–
Table 2. HLA allele frequencies of HLA-A, HLA-B, and HLA-DR
alleles with a (nearly) significant difference between controls
and cHL patients.
Controls cHL patients Controls vs cHL
n % n % (P-value*)
HLA-B5 798 5.3 55 8.3 8.961024
HLA-B37 277 1.8 23 3.5 2.761023
HLA-DR2 2152 16.4 146 21.7 3.161024
HLA-DR5 1224 9.3 86 12.8 2.861023
HLA-DR7 1320 10.1 35 5.2 3.7610225
*Significant differences (p,0.001) are shown in bold, suggestive ones
(p,0.003) in italic.
doi:10.1371/journal.pone.0039986.t002
Table 3. Allele frequencies of HLA-A, HLA-B, and HLA-DR alleles with (nearly) significant difference between controls and EBV+ or
EBV2 cHL subgroups.
Controls EBV+ cHL EBV2 cHL Controls vs EBV+ Controls vs EBV2
n % n % n % (P-value*) (P-value*)
HLA-A1 2667 17.7 52 33.3 85 18.3 3.561027 NS
HLA-A2 4828 32.0 25 16.0 153 33.0 2.161025 NS
HLA-B5+ 798 5.3 15 9.6 35 7.6 NS NS
HLA-B37 277 1.8 13 8.3 10 2.2 3.361029 NS
HLA-DR2 2152 16.4 29 18.6 106 22.9 NS 2.161024
HLA-DR5 1224 9.3 9 5.8 66 14.3 NS 3.661024
HLA-DR7 1320 10.1 7 4.5 26 5.6 NS 1.761023
HLA-DR10 118 0.9 6 3.8 5 1.1 1.461024 NS
+HLA-B5 is included because these alleles had significantly different frequencies in the total group of cHL cases compared with controls (Table 2). *Significant
differences (p,0.001) are shown in bold, suggestive ones (p,0.003) in italic.
doi:10.1371/journal.pone.0039986.t003
Table 4. HLA allele frequencies with a (nearly) significant
difference between EBV+ and EBV2 cHL patients.
EBV+ cHL EBV2 cHL p-value*
n % n %
HLA-A1 52 33.3 85 18.3 9.261025
HLA-A2 25 16.0 153 33.0 5.261025
HLA-B37 13 8.3 10 2.2 4.861024
HLA-Cw6 21 13.6 27 5.9 2.261023
*Significant differences (p,0.001) are shown in bold, suggestive ones
(p,0.003) in italic. HLA-Cw6 is included because it is part of a common
haplotypen in the Caucasian population.
doi:10.1371/journal.pone.0039986.t004
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0.44 for HLA-A*02 SSOPs and 2.31–3.49 for the HLA-A*01
SSOPs). Nevertheless, there was no significant difference between
the NS and the non-NS subgroups for these SSOPs (p-values for
interaction effects of SSOP by subtype on EBV status were all
.0.05).
LD of rs6903608 with HLA alleles
LD analysis of rs6903608 with the HLA typing revealed 15
significant associations (Table 6). Three of these associations were
in agreement with the HLA allele frequency results, i.e. HLA-
DR2, HLA-DR5 and HLA-DR7. The T allele was significantly
associated with HLA-DR7 (8.6% vs 0.2%, p= 5.961026). The C
allele was significantly associated with HLA-DR2 and HLA-DR5
(49% vs 0.5%, p,2610216 and 23% vs 4%, p= 4.6610212).
Eleven of the SNP / HLA allele associations, i.e. HLA-B7, HLA-
B8, HLA-C7, HLA-DR1, HLA-DR3, HLA-DR4, HLA-DR8,
DQB1, DQB2 and DQB4 were not significantly associated with
cHL in the HLA allele frequency analysis in this study. However,
HLA-DR4 was significantly associated with the total cHL group in
the phenotype analysis (see Supplementary data).
Figure 2. Genetic association of individual PCR-SSOP in EBV+ cHL. The p-value of each SSOP for differences in frequencies between EBV+
and EBV2 cHL cases is plotted on the y-axis. Genes are ordered according to their relative positions on the short arm of chromosome 6 (6p-telomere
to 6p-centromere). Strong associations with EBV status were present only for part of the PCR-SSOPs within the HLA-A gene.
doi:10.1371/journal.pone.0039986.g002
Figure 3. LD between the associated HLA-A SSOPs. Below the diagonal the r2 values are given and above the diagonal the D’ values. The SNPs
are sorted according the HLA-A allele specificity and strength of association with EBV status (same order as table 5). SSOPs C279–C241 in the left/
upper part are specific for HLA-A*02 and SSOPs C295–C332 in the right/lower are specific for HLA-A*01.
doi:10.1371/journal.pone.0039986.g003
HLA Association in EBV-Stratified Hodgkin Lymphoma
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Discussion
Inherited variations within the HLA genes as well as variations
in host immune responses have long been recognized to be
associated with susceptibility to disease, including cHL [27]. A
number of HLA genes, alleles and serotypes have previously been
reported to be involved in the pathogenesis of cHL [5–7] and
GWAS indicated the most significant associations for cHL to be
within the HLA locus [18,19]. In this study we observed multiple
associations that are specific for the EBV+, the EBV2 or the total
cHL subpopulations. HLA-B5 is a risk allele for cHL and HLA-
DR7 is a protective allele irrespective of the EBV status. HLA-
DR2 and HLA-DR5 are associated with an increased susceptibil-
ity in the EBV2 cHL groups. In the EBV+ cHL population an
increased susceptibility was observed for HLA-A1, HLA-B37 and
HLA-DR10, whereas resistance to disease development was
observed for HLA-A2.
Two GWAS indicated that rs6903608 was strongly associated
with the entire cHL population and the EBV2 cHL subpopula-
tion respectively [18,19]. To explore associations of the T and C
alleles with certain HLA alleles, we compared the SNP data of our
cohort to the HLA typing data and observed a significant LD with
15 HLA alleles (Table 6). Three of the 15 HLA alleles that were in
strong LD with rs6903609, i.e. HLA-DR2, HLA-DR5 and HLA-
DR7 were significantly associated with cHL in both the HLA allele
and phenotype frequency analysis. HLA-DR4 was only significant
in the phenotype analysis. The C-allele was frequently observed
together with HLA-DR2 or HLA-DR5, i.e. 71.4%
(48.5%+22.9%), while either HLA-DR allele was observed only
in 4.1% in combination with the T-allele. These two HLA alleles
were associated specifically with the EBV2 cHL subgroup in our
study. Since most cHL cases are EBV2, this association might
explain the SNP association seen in the total cHL irrespective of
EBV. Because the SNP was associated with many HLA alleles that
were themselves not associated with cHL, the strong association of
the SNP with cHL is probably caused by its strong LD with the
HLA-DR alleles and not vice versa. Thus, by applying HLA
typing we were able to identify the HLA genes and alleles that
underlie the strong genetic association identified in a recent
genome wide association study (GWAS) [18,19].
The previously reported association of the HLA-A gene with
EBV+ cHL [5,15,16] was confirmed both in comparison to EBV2
cHL and in comparison to healthy controls with an increased risk
for HLA-A*01 and a reduced risk for HLA-A*02. In contrast to
the Caucasian population, we identified a protective effect for
HLA2*02:07 for EBV2 cHL and a predisposing effect for HLA-
A*02:07 carriers for EBV+ cHL in the Chinese population [28].
The HLA-A*02(non02:07) typings showed no significant associa-
tions with either EBV stratified cHL. A tentative explanation for
the HLA-A*02 associations are the known cytotoxic T cell
responses to LMP1, LMP2 and lytic EBV derived antigenic
peptides presented in the context of most HLA-A*02 [9,29,30]
Table 5. Overview of PCR-SSOPs with significant differences between EBV+ and EBV2 cHL population.
SSOP Specificity of probea AA positions (IMGT) Potential contact position{ EBV+ (%) EBV2 (%) P OR
c279 A*02 9–12,23–25 Peptide (9,24) 23.0 50.0 4.361024 0.32
c348 A*02, A*68, A*69 141–142, 144–146 Peptide (146), TCR (145,146) 34.6 60.3 6.061024 0.37
c373 A*02, A*68, A*69 143–146, 150–153 Peptide (143,152), TCR
(145,146,150,151)
34.6 60.3 6.061024 0.37
c349 A*02 94–98 Peptide (95,97) 26.9 53.0 7.661024 0.36
c273 A*02, A*31, A*33, A*74 69–72, 76–79 Peptide (70,77), TCR (69,72,76,79) 31.6 58.2 8.161024 0.37
c339 A*02, A*24, A*68, A*69 150–154 Peptide (152), TCR (150,151,154) 48.7 71.6 2.061023 0.41
c397 A*02, A*23, A*24, A*68,
A*69
124–128 51.3 72.8 2.561023 0.41
c208 A*02 60–65 Peptide (62,63), TCR (61,62,65) 29.5 53.0 2.961023 0.41
c241 A*02 70–71, 73–74, 76 Peptide (70,73 74), TCR (76) 29.5 53.0 2.961023 0.41
c295 A*01, A*23, A*24, A*25,
A*26, A*30, A*32, A*36,
A*74
70–74 Peptide (70,73,74), TCR (72) 80.8 53.9 7.261025 3.79
c378 A*01 156, 158, 166–168 Peptide (156,167), TCR
(158,166,167)
56.4 29.9 1.361024 3.05
c325 A*01, A*36 150–152 Peptide (152)TCR (150,151) 56.4 30.2 1.461024 3.03
c375 A*01 161–163, 166–168 Peptide (163,167), TCR
(162,163,166,167)
56.4 30.2 1.461024 3.03
c281 A*01, A*36 41–44 55.8 29.3 1.761024 3.02
c395 A*01, A*03, A*11, A*30,
A*36
93–98 Peptide (95,97) 84.6 61.2 2.161024 3.79
c331 A*01, A*23, A*24 164, 166–168 Peptide (167), TCR (166,167) 71.8 47.0 3.461024 2.96
c215 A*01, A*26, A*29, A*36 74–77 Peptide (74,77), TCR (76) 59.0 35.5 1.061023 2.58
c211 A*01, A*03, A*11, A*30,
A*31, A*32, A*36, A*74
59–60, 62–64 Peptide (59,62,63), TCR (62) 87.2 68.0 1.661023 3.36
c332 A*01, A*11, A*25, A*26 160–163, 165 Peptide (163), TCR (162,163) 66.7 45.9 2.061023 2.49
aOnly CWD alleles were included; for complete probe reactivity see http://www.gen-probe.com/; {Contact position according to Bjorkman 1990.18. *Significant
differences (p,0.001) are shown in bold, suggestive ones (p,0.003) in italic.
doi:10.1371/journal.pone.0039986.t005
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types, with the exception of HLA-A*02:07. In contrast no HLA-
A*01 restricted cytotoxic EBV peptides have been found [31].
Analysis of the individual PCR-SSOPs revealed a significant
difference for 19 out of the 358 probes in EBV+ as compared to
EBV2 cHL. These probes discriminated between the HLA-A*01
and HLA-A*02 alleles and showed only a limited number of cross
reacting other alleles. The other, less significant HLA-A*01 and
HLA-A*02 identifying probes showed a similar risk pattern. The
lower significance level of these probes can be explained by their
broader specificities including some common HLA-A alleles. For
example, several probes share specificity for both HLA-A1 and
HLA-A11. HLA-A*11 was previously reported to be a protective
allele in EBV-associated undifferentiated nasopharyngeal carcino-
ma (UNPC) in both endemic and non-endemic regions [32,33].
UNPC has the same EBV latency pattern as cHL with expression
of only LMPs and EBNA1 and it was suggested that HLA-A*11
can efficiently present antigenic peptides from these proteins
[29,30]. Therefore, specificity of a probe for both HLA-A*11 and
HLA-A*01 might diminish the strength of its association with
EBV+ cHL. In combination with the LD analysis, we now showed
that there is no evidence that individual SNPs detected by the
PCR-SSOPs are important for the HLA-A*02 association,
indicating that the complete HLA-A*02 allele is important for
this association. For HLA-A*01 three clear independent signals
were observed, representing different allele specificities in addition
to the HLA-A*01 allele, i.e. HLA-A*23/*34 for C295 and C331,
HLA-A*03 for C395 and C211, and no additional specificities for
two of the five SSOPs of the third signal. The frequencies of the
shared HLA-A alleles were similar in EBV2 and EBV+ cHL cases
indicating that the HLA-A*01 specificity is the most likely
explanation for the observed associations.
The strong LD observed in the HLA region might affect the
results of our HLA association studies. The HLA-A1 antigen is
known to be in strong LD with HLA-B8 and in contrast to HLA-
A1, HLA-B8 is capable of presenting EBV-derived peptides [34].
We observed that in the EBV+ cHL population 53% (23/43) of
the HLA-A1 positive patients also carried the HLA-B8 allele,
whereas in the EBV2 cHL population this percentage was 66%
(46/70). In theory, presence of HLA-B8 in HLA-A1 carrying
EBV+ cHL might overcome the less effective presentation of EBV
derived peptides by HLA-A1. Despite this known LD we found a
very significant effect for HLA-A1 in this study consistent with
previous studies [5,15,16] and no significant differences for HLA-
B8. Haplotype analysis for A1-B8 also indicated no significant
differences. The capacity of HLA-B8 to present EBV-derived
peptides and the strong LD of HLA-B8 with HLA-A1 cannot
explain the observed association in EBV+ cHL cases with HLA-
A1.
The predisposing effects of HLA-B37 and HLA-DR10 for
EBV+ cHL might at least be partly attributed to their strong LD
with HLA-A1 since HLA-A1-B37-Cw6-DR10-DQ5 is a rather
common haplotype in the Caucasian population. In our study, 12
of 13 HLA-B37+ and five of six HLA-DR10+ EBV+ cHL patients
also carried HLA-A1. Haplotype analysis confirmed a significant
increase in the A1-B37-DR10 haplotype frequency in EBV+ cHL
(3.1%) as compared to controls 0.2% (p= 1.6610212). It should be
noted that this haplotype is only observed in a small proportion of
the HLA-A1 carriers and that despite the low p-value can not
account for the observed significant associations of HLA-A1 with
EBV+ cHL.
Two associations (HLA-B5 and HLA-DR7) were specific for the
total cHL subgroup irrespective of the EBV status. The HLA-B5
association has been reported previously [35]. Significant effects of
HLA-A1, HLA-B8, HLA-B18 and HLA-DR5 for cHL that have
been reported in previous publications [12–14,36] could not be
confirmed in the total patient group in our study. These
differences might be explained by differences in sample size,
patient selection, and proportion of EBV+ cases, since we found
HLA-A1 specifically in EBV+ cHL an HLA-DR5 specifically in
EBV2 cHL. Moreover, previous studies were carried out in
relatively small numbers of patients ranging from 11 to 137 within
different countries such as Egypt, Czech Republic, Sweden,
Denmark, and United States. Distribution of HLA alleles varies
widely by ethnicity and geography, which might lead to differences
in disease-associated HLA alleles among different ethnic groups
and geographic locations. A limitation of this approach is the
inability to discriminate between specific allele variants, which
might be more or less common in different populations.
The HLA-DR2 and HLA-DR5 class II associations were
specific for the EBV2 cHL subgroup. For HLA-DR5 we found a
non-significant opposite effect in EBV+ cHL. An association with
DRB1*15:01 has been reported previously to be associated with
familial NS subtype cHL [7]. HLA-DR2 is a broad allele that
includes the HLA-DR15 split allele and HLA-DR15 is the
serological name for the HLA-DRB1*15:01 typing. This previ-
ously reported association is thus similar to the association that we
found to be specific for EBV2 cHL.
The HLA-A1 and HLA-A2 class I associations were specific for
the EBV+ cHL subgroup, whereas the HLA class II associations
were specific for the EBV2 cHL subgroup. HLA class II
molecules present exogenous antigenic peptides to CD4+ helper
T cells, whereas HLA class I molecules bind and present peptides
derived from endogenous proteins to CD8+ cytotoxic T lympho-
Table 6. Association of the rs6903608 SNP alleles with HLA
alleles in 278 cHL patients.
HLA allele C-allele* T-allele* p-value
HLA-A n=244 n=310
1 13.4% 28.2% 2.761025
HLA-B n=241 n=307
7 34.2% 6.7% 4.4610216
8 8.1% 21.4% 2.061025
HLA-Cw n=237 n=301
7 51.6% 3.41% 2.161026
HLA-DR n=244 n=310
1 0.5% 17.6% 3.1610211
2 48.5% 0.5% ,2610216
3 4.3% 21.2% 9.261029
4 0.5% 22.2% 2.2610214
5 22.9% 3.6% 4.6610212
7 0.2% 8.6% 5.961026
8 0% 5.8% 1.361024
HLA-DQ n=243 n=307
1 71.7% 36.1% ,2610216
2 5.0% 25.0% 2.4610210
4 0% 5.2% 3.461024
HLA-DP n=244 n=310
1 0.8% 6.8% 1.361024
*Indicated are the number of alleles (the total number of alleles is 556).
doi:10.1371/journal.pone.0039986.t006
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cytes [27]. Our findings thus support a differential immunogenic
basis with a more prominent role in the effector phase of the
immune response for HLA class I in EBV+ cHL and an
immunoregulatory role for HLA class II in the pathogenesis of
EBV2 cHL. http://bloodjournal.hematologylibrary.org/cgi/
content/full/92/10/3515 – B31This suggests presence of a
specific HLA class II restricted antigen involved in the pathogen-
esis of EBV2 cHL. Whether this is a pathogen-derived antigen or
an antigen derived from a mutated protein remains unknown.
In conclusion, the current study confirms the previously
reported genetic association of the HLA-A1 and HLA-A2 in
EBV+ cHL. The genetic influence of these two HLA antigens is
more important than individual SNPs that might be shared by
multiple HLA-A alleles. In addition, we demonstrated two
significant associations (HLA-B5 and HLA-DR7) for the cHL
population and two significant HLA class II associations (HLA-
DR2 and HLA-DR5) specific for the EBV2 cHL population. The
two new associations for the EBV+ cHL subgroup (HLA-B37 and
HLA-DR10) are most likely related to the common haplotype
including HLA-A1. Overall, the haplotype analyses did not show
very strong associations as compared to analysis of the individual
genes. This indicates that the individual genes are responsible for
the associations between cHL and the HLA region. Our study
implies an influence of the interaction between environmental and
genetic risk factors in the development of cHL and supports
heterogeneity in the genetic predisposition to EBV+ and EBV2
cHL.
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